Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Published Date: 25 Sep 2025

There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same time period.

Read Full News

Todays Updates


Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH


Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli


Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD


Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy


FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS


AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo


Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs


Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates


Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH


Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli


Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD


Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy


FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS


AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo


Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs


Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study reveals increase in late-stage breast cancer diagnoses in US

2.

Using AI, one can find cancer risk factors.

3.

A promising medication could slow brain tumors in children.

4.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

5.

Prostate cancer therapies: AI-based image analysis detects early organ damage


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot